T Cells
T cells are central to cell-mediated immunity, and T cell–based immunotherapy is a rapidly growing field. Current therapies mainly use four approaches: CAR T cells, TILs, Tregs, and TCR-engineered T cells. Several CAR T and TCR therapies are already approved, initially for blood cancers, with the first solid tumor indication now authorized and many trials ongoing in cancer, chronic infection, and autoimmunity.
To support a smooth path from preclinical work to commercial manufacturing, Sartorius offers CellGenix® cytokines and growth factors in both preclinical and GMP grades. Our GMP cytokines come with documented purity, potency, consistency, and stability, plus expert regulatory and technical support to streamline raw material qualification. CellGenix® GMP recombinant cytokines are manufactured under applicable GMP guidelines and are suitable for use according to USP <1043>, Ph. Eur. 5.2.12, and ISO 20399:2022.
Test Growth Factor and Cytokines Samples for T Cells
Samples for cell and gene therapy as well as regenerative medicine.
| T Cell Growth Factors and Cytokines | ||
|---|---|---|
| IL-2 | More Info | Visit eShop |
| IL-7 | More Info | Visit eShop |
| IL-15 | More Info | Visit eShop |
| IL-21 | More Info | Visit eShop |
| TGF-β1 | More Info | Visit eShop |
IL-2
CellGenix® Recombinant Human IL‑2 (rh IL‑2) is an animal component–free cytokine that reliably activates and expands T cells, NK cells, and CIK cells. Both preclinical and GMP grades are manufactured in a dedicated animal-free GMP facility.
IL‑2 is mainly produced by T cells and is a key regulator of immune responses, involved in anti-inflammatory pathways, hematopoiesis, and tumor surveillance. In cell and gene therapy, IL‑2 supports proliferation and differentiation of CAR T, TCR T, Tregs, TILs, NK, and CIK cells.
IL-7
CellGenix® Recombinant Human IL‑7 (rh IL‑7) is an animal component–free cytokine that supports survival, proliferation, and differentiation of T cells and enhances NK cell survival. Both preclinical and GMP grades are manufactured in a dedicated animal-free GMP facility.
IL‑7 promotes differentiation of hematopoietic stem cells into lymphoid progenitors and drives proliferation of B, T, and NK cells. In cell and gene therapy, IL‑7 is used for ex vivo expansion of engineered T cells (e.g., CAR T cells), differentiation of iPSCs into T cells, and differentiation of cord blood–derived HSCs (CD34⁺) into NK cells.
IL-15
CellGenix® Recombinant Human IL‑15 (rh IL‑15) is an animal component–free cytokine that promotes T cell proliferation, stimulates NK cell expansion, and supports generation of CIK cells. Both preclinical and GMP grades are produced in a dedicated animal-free GMP facility.
IL‑15 is a key cytokine in humoral and adaptive immunity, driving differentiation, maintenance, and activation of NK cells and multiple T cell subsets. In cell and gene therapy, IL‑15 is used for ex vivo expansion of CAR T, TCR T, TIL, and NK cells, as well as for CIK cell generation.
IL-21
CellGenix® Recombinant Human IL‑21 (rh IL‑21) is an animal component–free cytokine that promotes proliferation of T cells and NK cells and enhances their cytotoxicity. Both preclinical and GMP grades are produced in a dedicated animal-free GMP facility.
IL‑21 is key to humoral and adaptive immunity, stimulating NK cells and multiple T cell subsets, especially cytotoxic T cells. Produced by activated CD4⁺ T helper and NKT cells, IL‑21 is used in cell and gene therapy for ex vivo expansion of T cells (including CAR T and TCR T) and NK cells.
TGF-β1
CellGenix® Recombinant Human TGF‑β1 (rh TGF‑β1) is an animal component–free cytokine that supports expansion of iPSCs, ESCs, MSCs, and regulatory T cells (Tregs) and drives T cell differentiation into Tregs. Both preclinical and GMP grades are produced in a dedicated GMP facility.
TGF‑β1, a member of the TGF‑β superfamily, regulates cell differentiation, proliferation, and apoptosis and is secreted by many immune cells, including T cells, B cells, macrophages, and monocytes. In cell and gene therapy, it is used to expand iPSCs, ESCs, MSCs, and Tregs.
CellGenix® rh TGF‑β1 is produced in a human amniocyte cell line (CAP®), enabling authentic human post‑translational modifications that cannot be achieved with bacterial expression systems.
